Ziv-aflibercept: binding to more than VEGF-A--does more matter?

Abstract

The VELOUR and VITAL studies recently demonstrated ziv-aflibercept improved overall survival in patients with metastatic colorectal cancer (mCRC), including those previously treated with bevacizumab, but did not improve overall survival in non-small-cell lung cancer. Thus, VEGF-directed agents might be useful throughout the continuum of care in mCRC, but biomarkers are needed to identify patients likely to benefit.

• Authors: Jeffrey M Clarke, Herbert I Hurwitz
• Journal: Nature reviews. Clinical oncology (Nat Rev Clin Oncol) Vol. 10 Issue 1 Pg. 10-1 (Jan 2013) ISSN: 1759-4782 [Electronic] England
• PMID: 23149898 (Publication Type: Journal Article)

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Recombinant Fusion Proteins
• VEGFA protein, human
• Vascular Endothelial Growth Factor A
• aflibercept
• Bevacizumab
• Receptors, Vascular Endothelial Growth Factor

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Carcinoma, Non-Small-Cell Lung (drug therapy, mortality, pathology)
• Clinical Trials, Phase III as Topic
• Colorectal Neoplasms (drug therapy, mortality, secondary)
• Humans
• Lung Neoplasms (drug therapy, mortality, pathology)
• Prognosis
• Receptors, Vascular Endothelial Growth Factor (therapeutic use)
• Recombinant Fusion Proteins (therapeutic use)
• Survival Rate
• Vascular Endothelial Growth Factor A (antagonists & inhibitors)